Politics
Pro-life leader expects FDA nominee Heidi Overton to increase scrutiny on mifepristone
Dr. Heidi Overton's upcoming confirmation hearing could signal changes to federal rules and safety reviews for abortion medication.
The short version
- John Mize, CEO of Americans United for Life, stated that FDA nominee Dr. Heidi Overton could bring renewed scrutiny and tighter restrictions to the abortion drug mifepristone.
- If confirmed, Overton will lead the ongoing FDA safety review of mifepristone that began in September 2025 following the resignation of former FDA Commissioner Dr. Marty Makary.
- The Senate is expected to hold Overton's confirmation hearing after returning from summer recess on September 14.
Key facts
- President Donald Trump nominated Dr. Heidi Overton, who currently serves as his deputy assistant for domestic policy, to lead the FDA.[Fox News]
- Overton previously criticized federal policies expanding access to abortion pills in a February 2023 policy brief for the America First Policy Institute.[Fox News]
- Former FDA Commissioner Dr. Marty Makary resigned in May 2023 after clashing with administration officials and facing criticism from pro-life activists over the pace of the agency's mifepristone safety review.[Fox News]
- Current FDA regulations permit mifepristone to be prescribed via telehealth and delivered through certified mail-order pharmacies.[Fox News]
- The FDA's ongoing safety review of mifepristone was initiated in September 2025 and has no set completion date.[Fox News]
What remains uncertain
- Whether Overton will alter current FDA regulations or attempt to revoke mifepristone's approval once confirmed remains undetermined.[Fox News]
- The precise timeline for the FDA to finalize its safety review of mifepristone is unconfirmed, though the agency notes such evaluations generally take a year or more.[Fox News]